AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. LLY
  4. [Form 4] Eli Lilly & Co. Insider Trading Activity

[Form 4] Eli Lilly & Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Filing content is currently unavailable.

Source:

Stock LLY logo
Lilly Eli & Co

NYSE:LLY

LLY Rankings

#14 Ranked by Market Cap
#1828 Ranked by Dividends

LLY Latest News

Aug 7, 2025
Lilly reports second-quarter 2025 financial results and raises guidance
Aug 7, 2025
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
Jul 31, 2025
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Jul 30, 2025
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Jul 29, 2025
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL

LLY Latest SEC Filings

Aug 8, 2025
[Form 4] Eli Lilly & Co. Insider Trading Activity
Aug 7, 2025
[10-Q] Eli Lilly & Co. Quarterly Earnings Report
Aug 7, 2025
[8-K] Eli Lilly & Co. Reports Material Event
Aug 4, 2025
[Form 4] Eli Lilly & Co. Insider Trading Activity
Jul 25, 2025
[Form 4] Eli Lilly & Co. Insider Trading Activity

LLY Stock Data

670.04B
945.62M
0.16%
84.16%
0.85%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
INDIANAPOLIS